News Sentiment

MBIO sentiment intelligence

Mustang Bio Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 44 Balanced news tone 47 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 0.63 Week of 17 Jul 2026
Weighted tone 44/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

77/100 classification confidence.

Company focus 38

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-10.7% over one week, -3.4% over four weeks, trend inactive, and below fair value.

Latest direct headline Negative

Mustang Bio stock trades lower as cash runway and trial update shape outlook

Market Reaction

Price moving ahead of tone

64/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 77/100 classification
One-week reaction -10.7% Price reacting lower
Trend fit Trend inactive -3.4% over four weeks
Fair value -97.7% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 4
Neutral 26
Negative 17

Relevance

Why the article matched

Direct first
Direct company coverage 38
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
TradingView 9
TradingKey 9
Market source 6
dars.gov.et 4
Quartr 3
Simply Wall Street 2
AD HOC NEWS 2
simplywall.st 2

Event Lens

What the news is about

Classified themes
Earnings 21
Market update 21
Balance sheet 3
Deals and strategy 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 47
Ad Hoc News Direct company coverage

Mustang Bio stock trades lower as cash runway and trial update shape outlook

Mustang Bio's stock is trading lower due to a limited cash runway, ongoing clinical trials for rare cancers and gene therapy, and the search for strategic options. The company reported $0 revenue in Q1 2026 but narrowed its net loss to $7.8 million, with a cash balance of $24 mil

Tone
Negative 36/100
Event
Earnings
Published
17 Jul 2026 18:38
Source
Ad Hoc News
Quartr Direct company coverage

Mustang Bio (MBIO) Registration Filing Summary

This article summarizes a Mustang Bio (MBIO) registration filing from November 29, 2025. It details the company's focus on cell and gene therapies, its significant accumulated deficit ($386.2 million as of March 31, 2024), and its ongoing efforts to raise capital through offering

Tone
Negative 13/100
Event
Market update
Published
08 Jul 2026 06:10
Source
Quartr
Quartr Direct company coverage

Mustang Bio (MBIO) Proxy Filing Summary

Mustang Bio (MBIO) has scheduled its Annual Meeting for December 22, 2025, to be held virtually, where stockholders will vote on key corporate matters. These include the election of seven directors, ratification of KPMG LLP as auditor, and amendments to the 2019 Employee Stock Pu

Tone
Negative 40/100
Event
Market update
Published
07 Jul 2026 20:41
Source
Quartr
Quartr Direct company coverage

Mustang Bio (MBIO) Q1 2026 earnings summary

Mustang Bio (MBIO) reported a net loss of $0.96 million for Q1 2026, an increase from $0.15 million in Q1 2025, despite a decrease in operating expenses. The clinical-stage biopharma company, which has no approved products or revenue, continues to develop novel therapies for canc

Tone
Negative 38/100
Event
Earnings
Published
07 Jul 2026 20:41
Source
Quartr
Simply Wall Street Direct company coverage

Mustang Bio (Nasdaq:MBIO) - Stock Analysis

Mustang Bio, Inc. (Nasdaq:MBIO) is a clinical-stage biopharmaceutical company focused on cell therapies for cancers and autoimmune diseases, with a current market cap of US$5.3 million. The company faces significant financial risks including low market cap, lack of revenue, share

Tone
Negative 40/100
Event
Earnings
Published
02 Jul 2026 04:10
Source
Simply Wall Street
TradingView Direct company coverage

Price to sales forward of Mustang Bio, Inc. – NASDAQ:MBIO

This article provides a brief snapshot of the "Price to sales forward" metric for Mustang Bio, Inc. (NASDAQ: MBIO). It indicates the period, value, and change associated with this financial ratio for the company, noting that the market is currently closed.

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 05:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Mustang Bio, Inc. – NASDAQ:MBIO

The article presents information regarding Mustang Bio, Inc. (NASDAQ:MBIO), specifically focusing on its enterprise value to EBIT forward. It appears to be a financial data snippet or a page from a financial tracking platform like TradingView, providing metrics for the pharmaceut

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 01:39
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of Mustang Bio, Inc. – NASDAQ:MBIO

This article references the enterprise value to EBITDA forward for Mustang Bio, Inc. (NASDAQ: MBIO). It lists the company on the Nasdaq Stock Market and provides general financial overview information. The content primarily consists of navigation links and stock market data discl

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 21:41
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Mustang Bio, Inc. – BOATS:MBIO

This article provides financial information for Mustang Bio, Inc. (MBIO) on the Blue Ocean Alternative Trade System (BOATS). It specifically highlights the company's enterprise value to EBIT forward. The data presented is provided by ICE Data Services and FactSet Research Systems

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 19:11
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Mustang Bio, Inc. – BOATS:MBIO

This article provides financial data, specifically the "Price to earnings forward," for Mustang Bio, Inc. (BOATS:MBIO) as listed on TradingView. It appears to be a stub or a data point within a larger financial platform, offering a snapshot of a single financial metric without fu

Tone
Neutral 50/100
Event
Earnings
Published
28 Jun 2026 14:39
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Mustang Bio, Inc. – NASDAQ:MBIO

This article provides financial information for Mustang Bio, Inc. (NASDAQ: MBIO), specifically focusing on its price-to-earnings forward valuation. It appears to be a financial data page from TradingView, showing market information and a general overview for the company. The cont

Tone
Neutral 50/100
Event
Earnings
Published
28 Jun 2026 06:40
Source
TradingView
TradingView Direct company coverage

Mustang Bio, Inc. Actuals & Estimates (NASDAQ:MBIO)

This article provides an overview of Mustang Bio, Inc. (NASDAQ:MBIO) stock, including its current price, historical performance, and financial estimates. It details market capitalization, volatility, upcoming earnings reports, and technical analysis, concluding with guidance on h

Tone
Negative 34/100
Event
Earnings
Published
25 Jun 2026 13:39
Source
TradingView
Simply Wall Street Direct company coverage

MBIO - A CAR-T Therapy Pipeline with Complete Remission (CR) Data Priced as a Negative Asset???

This article argues that Mustang Bio (MBIO) is significantly undervalued, trading below its cash and net asset value. The author highlights the clinical potential of MBIO's CAR-T therapy for glioblastoma, which has shown complete remission data, and the company's strategic pivot

Tone
Positive 72/100
Event
Balance sheet
Published
24 Jun 2026 14:11
Source
Simply Wall Street
TradingKey Direct company coverage

Mustang Bio Inc (MBIO) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Mustang Bio Inc (MBIO), highlighting its beta value of 2.08, indicating higher volatility compared to the S&P 500. While a formal risk assessment score is not yet available, the article details various metrics including VaR, maximum dra

Tone
Negative 38/100
Event
Market update
Published
22 Jun 2026 01:41
Source
TradingKey
TradingKey Direct company coverage

Mustang Bio Inc (MBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Mustang Bio Inc (MBIO), noting that no earnings forecast score is currently available, which is below the Biotechnology & Medical Research industry average of 8.13. The report indicates that relevant financial forecasting data for EP

Tone
Neutral 50/100
Event
Earnings
Published
21 Jun 2026 13:40
Source
TradingKey
TradingKey Direct company coverage

Mustang Bio Inc (MBIO) Institutional Confidence

This article from TradingKey focuses on the institutional confidence in Mustang Bio Inc (MBIO). It provides a table detailing significant institutional shareholders, the number of shares they hold, and the percentage change in their holdings. The institutional confidence score re

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 22:10
Source
TradingKey
TradingKey Direct company coverage

Mustang Bio Inc (MBIO) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides a historical overview of Mustang Bio Inc's (MBIO) dividends and stock splits. It notes that the company has distributed $0.00 in dividends over the past five years. The document also lists several past and future stock mergers for MBIO, including a 50-to-1 m

Tone
Negative 33/100
Event
Deals and strategy
Published
18 Jun 2026 21:40
Source
TradingKey
TradingKey Direct company coverage

Mustang Bio Inc (MBIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey attempts to provide a revenue breakdown for Mustang Bio Inc (MBIO) but states that relevant data regarding business segments, regional revenue, and profit contribution have not been disclosed by the company yet. It primarily serves as a placeholder fo

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 05:10
Source
TradingKey
TradingKey Direct company coverage

Mustang Bio Inc (MBIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Mustang Bio Inc (MBIO), focusing on its price momentum, support, resistance levels, and various technical indicators. It notes that MBIO's current price momentum score is 2.09, ranking low in its industry, and the stock is trading bet

Tone
Negative 30/100
Event
Market update
Published
16 Jun 2026 20:42
Source
TradingKey
TradingKey Direct company coverage

Mustang Bio Inc (MBIO) Valuation: PE, PB & Fair Value Analysis

Mustang Bio Inc (MBIO) has a current valuation score of 8.09, placing it 171st out of 388 in the Biotechnology & Medical Research industry. The company's P/E ratio is -1.47, indicating it is significantly below its recent high and above its recent low. However, relevant data for

Tone
Neutral 50/100
Event
Market update
Published
15 Jun 2026 08:40
Source
TradingKey
TradingKey Direct company coverage

Mustang Bio Inc (MBIO) Financial Health: Profitability & Balance Sheet Analysis

Mustang Bio Inc (MBIO) has a current financial score of 7.56, placing it 107th out of 388 in the Biotechnology & Medical Research industry. The company's financial status is considered robust, but its operating efficiency is low. Several key financial data points related to quali

Tone
Neutral 50/100
Event
Market update
Published
15 Jun 2026 08:40
Source
TradingKey
AD HOC NEWS Direct company coverage

Mustang Bio stock (US62815P1003): restructuring progress keeps spotlight on cash and pipeline

Mustang Bio is actively restructuring, selling assets, and refocusing its resources on core cell and gene therapy programs to stabilize its financial position. The company aims to advance its pipeline through clinical development, relying on external financing, collaborations, an

Tone
Neutral 50/100
Event
Balance sheet
Published
17 May 2026 16:40
Source
AD HOC NEWS
AD HOC NEWS Direct company coverage

Mustang Bio stock (US62815P1003): restructuring moves and Nasdaq relisting plan put focus back on cell therapy pipeline

Mustang Bio is repositioning itself through a reverse stock split and cost cuts to regain Nasdaq compliance and extend its cash runway. The company focuses on developing cell and gene therapies for cancer and rare diseases, emphasizing its CAR-T programs. While the restructuring

Tone
Neutral 50/100
Event
Balance sheet
Published
16 May 2026 10:09
Source
AD HOC NEWS